All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Prof. Marek Trneny | EBMT 2018 | What were the most interesting results from EBMT?
Bookmark this article
Prof. Marek Trneny discusses key results from the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation from the following abstracts:
- Abstract OS1-3: Monica Baile on behalf of GELTAMO: Lenalidomide together with R-ESHAP shows significant activity in relapsed/refractory DLBCL (ORR 65% and CR 37%), to note: on third of pts were not R/R but PRs only after the induction
- Abstract OS1-7: Enrico Derenzini on behalf of Italian centers: Pretransplant immune checkpoint activation (PD1/PDL1 and LAG3) is connected with worse outcome after alloSCT
- Abstract OS1-6: Leopold Sellner on behalf of LWP EBMT: Idelalisib treatment for follicular lymphoma as bridging before alloSCT is feasible, with 70% PFS and 71% OS at 12 months
- Abstract WP7-6: Anne-Claire Mamez on behalf of French-speaking Europe: Promising results of AlloSCT in T-cell lymphomas, n 284, 2years OS and PFS were 68% and 64% resp
What were the most interesting results from EBMT?
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
60 votes - 49 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox